Lorinda Simms

6.9k total citations · 3 hit papers
38 papers, 5.1k citations indexed

About

Lorinda Simms is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Lorinda Simms has authored 38 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Lorinda Simms's work include Lung Cancer Treatments and Mutations (17 papers), Colorectal Cancer Treatments and Studies (11 papers) and Cancer Treatment and Pharmacology (9 papers). Lorinda Simms is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Colorectal Cancer Treatments and Studies (11 papers) and Cancer Treatment and Pharmacology (9 papers). Lorinda Simms collaborates with scholars based in United States, Canada and Italy. Lorinda Simms's co-authors include Giorgio V. Scagliotti, Katherine P. Sugarman, Janusz Rolski, Christian Manegold, Johan Vansteenkiste, Joachim von Pawel, Keunchil Park, Bonne Biesma, U. Gatzemeier and Mauro Zukin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Management Science.

In The Last Decade

Lorinda Simms

38 papers receiving 4.9k citations

Hit Papers

Phase III Study Comparing Cisplatin Plus Gemcitabine With... 2008 2026 2014 2020 2008 2015 2009 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
    2008 2.5k citations Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology profile →
  2. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
    2015 652 citations Josep Tabernero, Takayuki Yoshino et al. The Lancet Oncology profile →
  3. The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
    2009 568 citations Giorgio V. Scagliotti, Frank V. Fossella et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lorinda Simms United States 18 3.6k 3.5k 997 848 372 38 5.1k
D. Johnston Canada 15 3.6k 1.0× 3.5k 1.0× 1.1k 1.1× 664 0.8× 463 1.2× 23 5.1k
Mircea Dediu Romania 19 5.1k 1.4× 4.8k 1.4× 1.6k 1.6× 894 1.1× 337 0.9× 55 6.6k
Maximiliano Van Kooten Argentina 9 3.7k 1.0× 3.3k 1.0× 1.1k 1.1× 623 0.7× 191 0.5× 14 4.5k
P. Lianes Spain 28 2.7k 0.7× 2.7k 0.8× 1.2k 1.2× 496 0.6× 634 1.7× 77 4.3k
Eng Huat Tan Singapore 22 4.7k 1.3× 4.6k 1.3× 1.7k 1.7× 1.0k 1.2× 732 2.0× 55 6.8k
Shinzoh Kudoh Japan 27 4.5k 1.3× 4.0k 1.1× 1.3k 1.3× 489 0.6× 310 0.8× 84 5.7k
Renato Martins United States 20 4.7k 1.3× 4.6k 1.3× 1.7k 1.7× 916 1.1× 363 1.0× 42 6.7k
Radj Gervais France 24 4.0k 1.1× 3.7k 1.1× 1.1k 1.1× 617 0.7× 271 0.7× 83 5.2k
Nick Thatcher United Kingdom 34 3.9k 1.1× 4.0k 1.1× 1.5k 1.5× 810 1.0× 365 1.0× 117 5.7k
Aleksandra Szczęsna Poland 23 4.2k 1.2× 4.4k 1.3× 1.2k 1.2× 665 0.8× 264 0.7× 73 5.8k

Countries citing papers authored by Lorinda Simms

Since Specialization
Citations

This map shows the geographic impact of Lorinda Simms's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorinda Simms with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorinda Simms more than expected).

Fields of papers citing papers by Lorinda Simms

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorinda Simms. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorinda Simms. The network helps show where Lorinda Simms may publish in the future.

Co-authorship network of co-authors of Lorinda Simms

This figure shows the co-authorship network connecting the top 25 collaborators of Lorinda Simms. A scholar is included among the top collaborators of Lorinda Simms based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorinda Simms. Lorinda Simms is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tabernero, Josep, Takayuki Yoshino, Allen Lee Cohn, et al.. (2015). Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. The Lancet Oncology. 16(5). 499–508. 652 indexed citations breakdown →
2.
Borgaonkar, Mark, et al.. (2015). Anti-tuberculous therapy for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews. CD000299–CD000299. 7 indexed citations
3.
Kim, Edward S., Marcus A. Neubauer, Allen Lee Cohn, et al.. (2013). Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. The Lancet Oncology. 14(13). 1326–1336. 50 indexed citations
4.
Simms, Lorinda, Helen Barraclough, & Ramaswamy Govindan. (2013). Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors. Journal of Thoracic Oncology. 8(6). 808–813. 30 indexed citations
5.
Kim, Edward S., Marcus A. Neubauer, Allen Lee Cohn, et al.. (2012). SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy.. Journal of Clinical Oncology. 30(15_suppl). 7502–7502. 3 indexed citations
6.
Barraclough, Helen, Lorinda Simms, & Ramaswamy Govindan. (2011). Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios. Journal of Thoracic Oncology. 6(6). 978–982. 61 indexed citations
7.
8.
9.
Scagliotti, Giorgio V., Thomas Brodowicz, Frances A. Shepherd, et al.. (2010). Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(1). 64–70. 190 indexed citations
10.
Scagliotti, Giorgio V., Thomas Brodowicz, Frances A. Shepherd, et al.. (2009). Pemetrexed is more effective in patients with nonsquamous non-small cell lung cancer (NSCLC) histology: an analysis of three large, randomized, phase III trials. Journal of Thoracic Oncology. 4(9). 3 indexed citations
11.
Syrigos, K., Johan Vansteenkiste, Joachim von Pawel, et al.. (2009). Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer. Annals of Oncology. 21(3). 556–561. 41 indexed citations
12.
Scagliotti, Giorgio V., Purvish Parikh, Joachim von Pawel, et al.. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(21). 3543–3551. 2487 indexed citations breakdown →
13.
Hirsch, Fred R., et al.. (2008). The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review. Journal of Thoracic Oncology. 3(12). 1468–1481. 174 indexed citations
14.
Paridaens, Robert, Luc Dirix, Herlinde Dumez, et al.. (2007). Phase I/II Pharmacokinetic Study of Pemetrexed and Epirubicin in Patients with Locally Advanced or Metastatic Breast Cancer. Clinical Breast Cancer. 7(11). 861–866. 5 indexed citations
15.
Scagliotti, Giorgio V., Joachim von Pawel, Bonne Biesma, et al.. (2007). PRS-03: Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S306–S306. 19 indexed citations
16.
Llombart‐Cussac, Antonio, Miguel Martín, Nadia Harbeck, et al.. (2006). Randomized, phase II study of two doses of pemetrexed as first-line chemotherapy for locally advanced or metastatic breast cancer (MBC): Clinical results and exploratory pharmacogenomic analysis. Journal of Clinical Oncology. 24(18_suppl). 3077–3077. 2 indexed citations
17.
Simms, Lorinda, et al.. (2001). Effect of Alosetron on the Pharmacokinetics of Alprazolam. The Journal of Clinical Pharmacology. 41(4). 452–454. 10 indexed citations
18.
Simms, Lorinda, et al.. (2001). Effect of Alosetron on the Pharmacokinetics of Fluoxetine. The Journal of Clinical Pharmacology. 41(4). 455–458. 10 indexed citations
19.
Borgaonkar, Mark, et al.. (1999). Anti-tuberculous therapy for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews. CD000299–CD000299. 22 indexed citations
20.
King, E. P., C. B. Sampson, & Lorinda Simms. (1975). An Alternative to Monte Carlo Sampling in Stochastic Models. Management Science. 21(6). 649–657. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Johnston Breakdown of academic impact, for papers by Mircea Dediu Breakdown of academic impact, for papers by Maximiliano Van Kooten Breakdown of academic impact, for papers by P. Lianes Breakdown of academic impact, for papers by Eng Huat Tan Breakdown of academic impact, for papers by Shinzoh Kudoh Breakdown of academic impact, for papers by Renato Martins Breakdown of academic impact, for papers by Radj Gervais Breakdown of academic impact, for papers by Nick Thatcher Breakdown of academic impact, for papers by Aleksandra Szczęsna
Rankless by CCL
2026